A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants
Latest Information Update: 05 Aug 2025
At a glance
- Drugs Bimagrumab/tirzepatide (Primary) ; Bimagrumab; Tirzepatide
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 18 Jul 2025 Planned End Date changed from 1 Nov 2025 to 1 Sep 2025.
- 18 Jul 2025 Planned primary completion date changed from 1 Nov 2025 to 1 Sep 2025.
- 18 Jul 2025 Status changed from recruiting to active, no longer recruiting.